Assessment of STELARA (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort

Trial Profile

Assessment of STELARA (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms PsaBio
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results (n=563) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 13 Nov 2017 Planned End Date changed from 21 Dec 2020 to 30 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top